Ask AI

Myelofibrosis: From Disease Biology and Risk Stratification to JAK Inhibitor Selection, Symptom Control, and Individualized Patient Care

Text Module
Text Module Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: August 25, 2026

Expiration: February 24, 2027

See Activity Collection

This activity reviews the biology and clinical course of myelofibrosis, including JAK-STAT pathway dysregulation, prognostic risk stratification, symptom and cytopenia burden, and the role of molecular and clinical features in treatment planning. Here, an expert examines pivotal and contemporary evidence supporting the use of JAK inhibitors, including ruxolitinib, pacritinib, momelotinib, and fedratinib, with attention to spleen volume reduction, symptom improvement, hematologic considerations, survival outcomes, and agent selection based on platelet count, anemia, transplant eligibility, and other patient-specific factors. The activity also addresses supportive care, quality-of-life burden, health disparities, and the importance of aligning treatment goals with patient preferences, helping learners apply available evidence to individualized management decisions across the myelofibrosis disease spectrum.

Myelofibrosis Biology to Treatment

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with MF do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old male construction worker presents with fatigue and splenomegaly. He follows up intermittently with his primary care professional, and his last known normal complete blood count was more than 6 years ago. He has lost 15 lb in the last 6 months because of early satiety. He is unable to complete a full workday and has to take multiple breaks​. His white blood cell count is 3.5 x 103/µL, hemoglobin is 8.2 g/dL, and platelets are 45 x 109/L. The patient is diagnosed with MF.

Given his symptomatic splenomegaly, hemoglobin of ​8.2 g/dL, and platelet count of 45 x 10⁹/L, which treatment strategy is most appropriate?​